Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06296875

The Krill Ageing Muscle Mechanisms (KAMM) Study

This study aims to determine the mechanisms via which krill oil supplementation increases muscle strength and whether this translates to improvements in gait and functional characteristics in older adults. The studies we will carry out will establish, in healthy older adults, the effects of 6 months of supplementation with krill oil

Objective 1) Muscle structure and function Hypothesis: Krill oil supplementation will increase muscle size and strength alongside positive changes in muscle architecture (pennation angle and fascicle length).

Objective 2) Neuromuscular control and central nervous system (CNS) function Hypothesis: Krill oil supplementation will improve Neuromuscular Junction (NMJ) transmission stability and increase central drive and intramuscular coherence, as a measure of muscle synergy.

Objective 3) Gait and functional characteristics Hypothesis: Krill oil supplementation will improve gait and functional characteristics.

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Glasgow

Glasgow, United Kingdom

Location status: Recruiting

Location contact

Stuart R Gray, PhD

CONTACT

[email protected]

01413302569

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • body mass index (BMI) </= 30 kg/m2
  • Age >/= 65 years
  • Capacity to consent
  • Living within the Glasgow area

Exclusion criteria

  • Diabetes mellitus
  • Severe cardiovascular disease
  • Seizure disorders
  • Uncontrolled hypertension (>150/90mmHg)
  • Active cancer or cancer that has been in remission <5 years
  • Participation in any resistance exercise training within the last 6 months
  • Impairments which may limit ability to perform assessments of muscle function
  • Dementia
  • Fish/shellfish allergy
  • Taking medication known to affect muscle (e.g. steroids, Selective serotonin reuptake inhibitors) or anticoagulants (e.g. warfarin)
  • Taking omega-3 supplements in the last 3 months
  • Regularly consuming 1 or more portions of oily fish per week
  • Not able to understand English

Treatment and study plan

Vegetable oil

Dietary Supplement

mixed vegetable oil

Krill oil

Dietary Supplement

Krill oil

Other names: (SuperbaBoost)

Primary outcomes

  1. Grip strength

    Time frame: Change from baseline to 24 weeks

    We will measure grip strength using a handgrip dynamometer, making 3 maximal contractions in each hand, with the dominant hand recorded. The highest grip strength will be used in analysis.

  2. Neuromuscular junction transmission instability

    Time frame: Change from baseline to 24 weeks

    We will assess peripheral motor unit (MU) characteristics in the vastus lateralis muscle using intramuscular electromyography

  3. Gait speed

    Time frame: Change from baseline to 24 weeks

    We will measure gait speed using a gaitrite connected mat during a 4 m walk test and the timed up and go test at usual speed.

Secondary outcomes

  1. Knee extensor maximal torque

    Time frame: Change from baseline to 24 weeks

    We will measure the muscle strength of the knee extensor muscles during a maximal voluntary contraction (MVC)

  2. Vastus lateralis muscle cross sectional area

    Time frame: Change from baseline to 24 weeks

    We will measure this using ultrasound

  3. Vastus lateralis pennation angle

    Time frame: Change from baseline to 24 weeks

    We will measure this using ultrasound

  4. Vastus lateralis fascicle length

    Time frame: Change from baseline to 24 weeks

    We will measure this using ultrasound

  5. Erythrocyte fatty acid composition

    Time frame: Change from baseline to 24 weeks

    Blood samples (15 ml each visit) will be collected

  6. Knee extensor force steadiness

    Time frame: Change from baseline to 24 weeks

    During the contractions to measure NMJ transmission instability we will also calculate force steadiness, as a measure of neuromuscular control

  7. Vastus lateralis motor unit conduction velocity

    Time frame: Change from baseline to 24 weeks

    will be measured using High Density surface electromyography (HDsEMG) during submaximal (10%, 30%, 50% and 70% of MVC) and during the MVC

  8. Vastus lateralis and vastus medialis intramuscular coherence

    Time frame: Change from baseline to 24 weeks

    Motor unit spike train will be measured using the surface electromyography (sEMG) electrodes while participants exert 20% of maximum voluntary contraction

  9. Hand flexor muscles intermuscular coherence

    Time frame: Change from baseline to 24 weeks

    Intermuscular coherence will be measured for 1 min on 20% of MVC using sEMG electrodes.

  10. Cortico-muscular coherence between sensory motor cortex and hand extensor muscles

    Time frame: Change from baseline to 24 weeks

    Cortico-muscular coherence is a derived measure, based on measurement of the electroencephalography (EEG) and motor unit spikes. EEG electrodes will be placed over the motor area of hands and worn during hand contractions

  11. Femoral Nerve Stimulation

    Time frame: Change from baseline to 24 weeks

    Single stimuli will be delivered to the muscle while participants maintain a 20% MVC isometric contraction, and the intensity of stimulation was increased until a plateau in twitch amplitude and rectus femoris M-wave (Mmax) occurs. Supramaximal stimulation will then be delivered by increasing the final stimulator output intensity by a further 30%.

  12. Transcranial Magnetic Stimulation (TMS)

    Time frame: Change from baseline to 24 weeks

    Motor evoked potentials (MEPs) will be elicited in the rectus femoris of the dominant leg via single pulse TMS and assessed using electromyographic (EMG) recordings.

  13. TMS Inhibition

    Time frame: Change from baseline to 24 weeks

    corticomotor inhibition during the MVCs a single TMS stimulation will be delivered over the motor cortex.

  14. TMS Excitation

    Time frame: Change from baseline to 24 weeks

    For assessment of corticospinal excitability, participants will maintain a 20% MVC isometric contraction while 20 single TMS pulses, separated by 6 s, will be delivered over the motor cortex

  15. Gait characteristics during 4m walk test and the timed up and go test

    Time frame: Change from baseline to 24 weeks

    The 4 m walk test involves participants walking a 4m distance at a normal walking pace, walking through the 4m line at the end of the gaitrite mat. The Timed Up and Go test (timed version of the Get Up and Go test) involves the participant sitting on a chair getting up, walking 3 meters in front of them across the gaitrite mat, returning to the chair and sitting down. The Theia markerless system will be used to extract Gait parameters

  16. Gait cycle with leg support parameters

    Time frame: Change from baseline to 24 weeks

    We will also get posture information from the 3D skeleton measurements and balance (pitch and roll) which are important in assessing fall risks and functional gait.

Study contacts

Contact information is provided by the study sponsor or research team.

Stuart Gray

CONTACT

[email protected]

+441413302569

Sponsors and collaborators

Lead sponsor

University of Glasgow

Other

Registry information

Official study title

Uncovering the Mechanisms Through Which Krill Oil Increases Muscle Function in Older Adults.

Acronym: KAMM

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Mar 6, 2024
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.